Sarkar R, Gordon D, Stanley J C, Webb R C
Department of Physiology, University of Michigan Medical Center, Ann Arbor 48109-0622, USA.
J Hypertens. 1997 Mar;15(3):275-83. doi: 10.1097/00004872-199715030-00009.
To determine the cell cycle specificity and intracellular mechanisms involved in inhibition by nitric oxide (NO) of vascular smooth muscle cell mitogenesis.
Cultured rat aortic smooth muscle cells were synchronized by serum withdrawal, treated with the NO donor S-nitroso-N-acetylpenicillamine and the cyclic GMP analog 8-Br-cGMP at various times during cell cycle progression, and DNA synthesis measured during the S phase. Two additional NO donors, 5-nitroso-glutathione and diethylamine NONOate, were used to confirm the inhibition of DNA synthesis by S-nitroso-N-acetylpenicillamine, and the ability of two antagonists of free NO to reverse the effects of NO donors was also evaluated. Bypass of ribonucleotide reductase by use of exogenous deoxynucleosides was attempted to determine whether inhibition of this S-phase enzyme was the mechanism by which NO inhibited DNA synthesis during the S phase.
Vascular smooth muscle cell mitogenesis was inhibited by cyclic GMP (cGMP) up to late G1 phase of the cell cycle, which corresponded to the point of greatest sensitivity to exogenous NO. In contrast to cGMP, three different NO donors inhibited DNA synthesis when added to cells synchronized in S phase, beyond the restriction point of cell cycle control in late G1 phase. This S-phase inhibition was reversible by removal of the NO donor or addition of two NO antagonists and was not observed with non-NO analogs of the donors. Inhibition by NO donors in S phase was neither reversed by the guanylate cyclase inhibitor methylene blue nor mimicked by exogenous cGMP. The S-phase inhibition by all three NO donors was reversed partially by bypass of ribonucleotide reductase, establishing this enzyme as an S-phase target of NO.
These findings demonstrate that NO inhibits smooth muscle mitogenesis by cGMP-dependent and -independent mechanisms acting at distinct points in the cell cycle. NO is the first endogenous substance to have been shown to inhibit mitogenesis beyond the restriction point in late G1 phase, suggesting that it plays a role in regulation of cells that have lost normal mechanisms of G1 growth control, such as the hyperproliferative smooth muscle cells noted in hypertension and restenosis.
确定一氧化氮(NO)抑制血管平滑肌细胞有丝分裂的细胞周期特异性及细胞内机制。
通过血清饥饿使培养的大鼠主动脉平滑肌细胞同步化,在细胞周期进程的不同时间用NO供体S-亚硝基-N-乙酰青霉胺和环鸟苷酸类似物8-溴-cGMP处理,在S期测量DNA合成。使用另外两种NO供体5-亚硝基谷胱甘肽和二乙胺NONOate来证实S-亚硝基-N-乙酰青霉胺对DNA合成的抑制作用,还评估了两种游离NO拮抗剂逆转NO供体作用的能力。尝试通过使用外源性脱氧核苷绕过核糖核苷酸还原酶,以确定抑制这种S期酶是否是NO在S期抑制DNA合成的机制。
环鸟苷酸(cGMP)抑制血管平滑肌细胞有丝分裂直至细胞周期的G1期晚期,这与对外源性NO最敏感的时间点相对应。与cGMP相反,三种不同的NO供体添加到同步于S期的细胞中时,在G1期晚期细胞周期控制点之后抑制了DNA合成。这种S期抑制可通过去除NO供体或添加两种NO拮抗剂来逆转,而供体的非NO类似物则未观察到这种抑制作用。NO供体在S期的抑制作用既不能被鸟苷酸环化酶抑制剂亚甲蓝逆转,也不能被外源性cGMP模拟。所有三种NO供体在S期的抑制作用通过绕过核糖核苷酸还原酶而部分逆转,确立了该酶为NO在S期的作用靶点。
这些发现表明,NO通过在细胞周期不同点起作用的cGMP依赖性和非依赖性机制抑制平滑肌有丝分裂。NO是首个被证明在G1期晚期控制点之后抑制有丝分裂的内源性物质,这表明它在调节那些失去正常G1期生长控制机制的细胞中发挥作用,例如高血压和再狭窄中出现的过度增殖的平滑肌细胞。